Viewing time: 4 minutes
“Our study replicates the trial results and provides reassurance to NMOSD patients that these treatments provide effective disease control without serious adverse events in the real world. ”
Previous studies from clinical trials have demonstrated the efficacy of novel monoclonal antibodies (MAbs) such as eculizumab (Soliris, Alexion) in patients with aquaporin 4 (AQP4) immunoglobulin G (IgG)-positive neuromyelitis optica spectrum disorder (NMOSD). It is listed. satralizumab (Enspryng; Genentech), and inebilizumab (Uplizna; Amgen). However, there is a lack of literature regarding real-world experience with these treatments. However, a recent real-world study conducted by senior author Amy Kunchok, MD, and colleagues demonstrated the strong efficacy and tolerability of his nMAb in the treatment of AQP4-IgG + NMOSD compared to rituximab. was shown.1 Although these results support the efficacy and tolerability of the approved nMAbs to treat AQP4-IgG+ NMOSD, the authors recommend further studies on long-term treatment outcomes.
The paper presented by Kunchok at the 2024 American Committee on Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held from February 29 to March 2, included 88 patients with AQP4-IgG+ NMOSD and Treatment included rituximab (n = 69), inebilizumab (n = 9), eculizumab (n = 5), and satralizumab (n = 5). Median age was 58 years, and there was no difference between rituximab and the new MAb (P = 0.058). Among the novel MAb group (n = 19), 84% (n = 16) of patients were on conventional immunosuppressive therapy and 16% were treatment naive. The authors noted that the main reported reason for switching treatment to novel MAbs was clinical relapse (75%).
Kunchok, a staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis, recently heard the following story: neurology live® will further discuss in the forum how studies have evaluated the efficacy and safety of novel monoclonal antibodies in patients with NMOSD. She also discussed why it is essential to evaluate real-world data beyond existing randomized controlled trials. Kunchok also discussed important implications for NMOSD patients based on her research findings.
Click here for more information about ACTRIMS 2024.